Inclusion Criteria:  Histopathologically confirmed IDH wild type glioblastoma, first recurrence after standard chemoradiation; suitable for standard-of-care re-resection; Age ≥ 18 years; Able and willing to give written informed consent; Life expectancy >3 months, allowing adequate follow-up of toxicity evaluation and antitumor activity; KPS performance status ≥70.  Exclusion Criteria:  Currently actively treated in another antitumor clinical trial (excluding DRUP and STELLAR studies); Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in medication studies or which could jeopardize compliance with study requirements including, but not limited to ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.